Analytical Procedure Development
ICH Q14 describes science- and risk-based approaches to developing and maintaining analytical procedures suitable for their intended use. It defines the minimal and the enhanced (analytical QbD) development approaches, the analytical target profile (ATP), method operable design region concepts, robustness, and change management across the procedure lifecycle. It is the companion to the validation guideline Q2(R2) and supports flexible post-approval change regulatory strategies.
What this does not cover
stated in the document's own scope- Does not set validation acceptance characteristics — that is ICH Q2(R2)
- Does not define product development — see ICH Q8/Q11
- Does not itself grant post-approval change flexibility; the regulatory mechanism is ICH Q12/regional rules
- Does not prescribe a specific analytical technology
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH Q14 describes approaches to the development of analytical procedures and their management across the lifecycle. It defines a minimal (traditional) approach and an enhanced approach (often called analytical quality by design), including the analytical target profile (ATP), evaluation of analytical procedure parameters and their ranges, robustness, and the establishment of a control strategy for the procedure. It also discusses how a well-understood procedure can support flexible regulatory change management for post-approval analytical changes. Q14 is the development companion to the validation guideline ICH Q2(R2), and the two were finalised together.
Legal basis & how it acquires force
Q14 is an ICH guideline implemented through regional adoption — an FDA guidance for industry and a CHMP-adopted guideline in the EU, among others. It interprets expectations for analytical procedures within the marketing-authorisation and GMP frameworks and connects to ICH Q8-Q12 and Q2(R2); it does not itself constitute a legal predicate rule.
Document structure
| Part | Covers |
|---|---|
| Introduction and scope | Purpose, minimal vs enhanced approaches, applicability |
| Analytical target profile | Defining required measurement performance (the ATP) |
| Development approaches | Parameter evaluation, ranges, robustness, method understanding |
| Control strategy | System suitability, set points, ongoing performance verification |
| Lifecycle and change management | Reporting-category proposals for post-approval changes |
Key requirements
- Define an analytical target profile (ATP) stating the required performance of the measurement
- Select minimal or enhanced development approach and justify the choice
- Identify and evaluate analytical procedure parameters and their effect on performance
- Establish appropriate set points, ranges, and system suitability criteria
- Assess robustness and, where used, define the proven ranges of the method
- Document a control strategy for the analytical procedure
- Define change management supporting reporting-category proposals for post-approval changes
Implementation tips
- Write the ATP before selecting the technique — it anchors development and later change justifications
- Use the enhanced approach where it earns regulatory flexibility, not as a default for every method
- Pair Q14 development knowledge with Q2(R2) validation so the submission tells one continuous story
- Capture robustness data that will support future analytical changes without a prior-approval supplement
International alignment
Q14 is harmonised across ICH members and finalised alongside Q2(R2). It aligns with the ICH quality lifecycle guidelines — notably Q8 (pharmaceutical development), Q9 (risk management), Q10 (quality system), and Q12 (lifecycle management) — and is implemented regionally by FDA, EMA and others.
ICH Q14: frequently asked questions
Quick answers to common questions about ICH Q14.
What is an ATP?
The analytical target profile: a prospective summary of the performance characteristics a procedure must meet for its intended purpose.
Is the enhanced approach mandatory?
No. Q14 permits a minimal approach or an enhanced (analytical QbD) approach; the enhanced approach can support greater regulatory flexibility.
What is Q14 paired with?
ICH Q2(R2), the validation guideline; development (Q14) and validation (Q2(R2)) are intended to be used together.